Prostate Cancer | Specialty

The Future of MRI in Prostate Cancer

July 27th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the future of MRI in prostate cancer.

Dr. Chi Discusses the LATITUDE Study in Metastatic Prostate Cancer

July 25th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the LATITUDE study in metastatic prostate cancer.

Expert Discusses Biomarker Development in GU Cancers

July 24th 2017

William Oh, MD, reviews some of the biomarkers under investigation in GU cancers and possibilities for major advances in the field over the next few years.

Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC

July 21st 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

Dr. Kane on Challenges Facing Genetic Testing in Prostate Cancer

July 19th 2017

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.

Dr. Stephenson on the Significance of a Study on Localized Prostate Cancer

July 19th 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer.

Dr. Dreicer on Ongoing Trials in Prostate Cancer

July 19th 2017

Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

Epigenetic Assay Could Spare Patients From Additional Biopsies for Prostate Cancer

July 17th 2017

A new test that can detect the existence of tumor activity is gaining credibility as a means of confirming the results of prostate biopsies, which have the potential to miss tumor cells.

Dr. Klein on Precision Medicine for Prostate Cancer

July 13th 2017

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.

Dr. Loeb on Determining Beneficial Test Options for Prostate Cancer

July 11th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses how to determine which test will be beneficial for the management of prostate cancer.

Findings Highlight Efficacy of Sipuleucel-T in African-American Men With Prostate Cancer

July 11th 2017

Oliver Sartor, MD, discusses the analysis of African-American men receiving sipuleucel-T for castrate-resistant prostate cancer compared with Caucasians, and the implications of this research.

Dr. Agarwal on Potential Agents for Metastatic Hormone-Sensitive Prostate Cancer

July 11th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses potential agents for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Chi on Combinations with Androgen Deprivation Therapy for Prostate Cancer

July 7th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses combinations with androgen deprivation therapy for patients with prostate cancer.

Dr. Stephenson on Patient Preferences on Undergoing Active Surveillance for Prostate Cancer

July 6th 2017

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses patient preferences with undergoing active surveillance versus active treatment for their prostate cancer.

Dr. Higano on Radium-223 for Prostate Cancer

June 27th 2017

Celestia Higano, MD, professor of Medicine and Urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses radium-223 for patients with prostate cancer.

Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

June 27th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Future Directions in Treating Advanced Prostate Cancer

June 26th 2017

Radium-223 in Combination Therapy for mCRPC

June 26th 2017

Radium-223 in mCRPC

June 26th 2017

Future of PARP Inhibitors in mCRPC

June 26th 2017